Dr Mike Nicholds, CEO talks about the inspiration and drive behind the company and the mission to improve in vitro to clinical translation
Company News:
Growth investment of £2.35m following strong growth
In Dec 2023 Newcells closed a growth capital investment round from existing investors. The company grew 56% last year driven by high demand for all its services and products, and the investment will underpin scalability by investments in automation, extend the high-content imaging capabilities and grow the team. Read the press release here
Newcells is proud to be highlighted as one of the University spin-out companies that contributed £5.2 billion to the UK's economy in a report from the Biotechnology and Biological Sciences Research Council (BBSRC) - Read the press release here.
Technology Spotlight:
Predicting potential nephrotoxicity of novel antibiotics
New and safe antibiotics are urgently needed. Find out how our proximal tubule model has demonstrated the ability to successfully predict kidney toxicity to de-risk the selection of novel clinical candidates
Paper Alert:
Development of Highly Differentiated Human Primary Proximal Tubule MPS Model (aProximate MPS Flow)
Our scientists have developed a physiologically relevant micro-physiological system (MPS) model of the human Proximal Tubule cells (hPTCs),
By designing a unique device that allows the use of industry standard TranswellsTM, primary hPTCs are subjected to fluidic media low and shear stress of 0.01-0.2 Pa. We observe that these cells replicate the polarity of hPTCs and exhibit higher expression of all the key transporters, compared with cells grown under static conditions and improves the phenotype.
Our data suggest that growing hPTCs under media flow significantly improves the phenotype and function of hPTC monolayers and has benefits to the utility and near-physiology of the model.
Conferences we will be attending:
SOT 63rd Annual Meeting
11th March 2024 - 13 March 2024
Salt Lake City, UT, USA View Event
Visit us at booth #1503 to discuss our in vitro solutions for safety assessment with Dr Colin Brown, Heidi Strona, Rhys Powell and Robert Liang
3D Cell Culture & Organ Modelling 2024
18th March 2024 - 19 March 2024
London, UK View Event
We look forward to welcoming you at booth #6 to discuss our unique organoid and 3D models of the kidney, retina and lung.
6th CKD Summit
9th March - 21 March 2024
Boston, MA , USA View Event
Recommended by LinkedIn
Dr Kathryn Garner will be presenting her talk titled 'A Human Primary In vitro Model of the Glomerular Filtration Barrier for Disease Modelling'
Visit us at booth #9
Meet our new Chief Marketing Officer, Dr Emanuela Costigliola
We are thrilled to announce that Dr Emanuela Costigliola has joined the executive team of the company as Chief Marketing Officer. Emanuela joins at a time of continuing growth to further develop and execute Newcells’ ambitious strategic marketing plans and strengthen their market leadership as experts in complex translational in vitro models.
Get to know our team:
We love our science and we equally love getting involved in charity events so recently participated in a charity football match and fundraised £600 in donations for OSCAR's Paediatric Brain Tumour Charity.
Find out more about the team that stands behind Newcells Biotech technology
Coming Soon: Lung Ebook
A comprehensive detailing our in vitro lung model platform.
Beat the rush and sign up today to receive a preview to gain unique insights into our fibroblast to myofibroblast transition (FMT) assay and small airways (SAEC) models.
Visit our website to find out more about our in vitro models
Kidney Nephron Models
Screen your drugs using multi-species models of the glomerulus and proximal tubule to gain predictive insights on safety, pharmacokinetics, and efficacy
Retina Models
A human iPSC derived suite of organoid and 3-D models capable of modelling retinopathies for efficacy and safety studies
Lung Airway Models
Use our platform of lung models and assays to understand efficacy in pulmonary fibrotic diseases in high-throughput and high-content formats.